Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
Organon (NYSE: OGN), a global healthcare company focused on women's health, has announced the appointment of Ramona A. Sequeira to its Board of Directors, effective July 1, 2025. Sequeira, currently President of the Global Portfolio Division at Takeda Pharmaceutical Company, will serve on the Board's Talent Committee.
The appointment expands Organon's Board to 12 directors. Sequeira brings over 30 years of pharmaceutical industry experience, including 20 years at Eli Lilly and 10 years at Takeda. At Takeda, she leads business units across Europe, Canada, China, and Growth and Emerging Markets, while overseeing the Vaccines Business Unit and Global Medical and Commercial Strategy functions.
Sequeira's notable achievements include being the first woman to Chair the Pharmaceutical Research and Manufacturers of America Board of Directors. She currently serves on the Board of Directors of Edwards Life Sciences.
Organon (NYSE: OGN), un'azienda globale nel settore sanitario focalizzata sulla salute femminile, ha annunciato la nomina di Ramona A. Sequeira nel suo Consiglio di Amministrazione, a partire dal 1° luglio 2025. Sequeira, attualmente Presidente della Divisione Portafoglio Globale presso Takeda Pharmaceutical Company, farà parte del Comitato Talenti del Consiglio.
La nomina porta il numero dei membri del Consiglio di Organon a 12. Sequeira vanta oltre 30 anni di esperienza nell'industria farmaceutica, di cui 20 anni in Eli Lilly e 10 anni in Takeda. In Takeda, guida unità di business in Europa, Canada, Cina e nei mercati in crescita ed emergenti, supervisionando inoltre l'unità Vaccini e le funzioni di Strategia Medica e Commerciale Globale.
Tra i suoi risultati più significativi, Sequeira è stata la prima donna a presiedere il Consiglio di Amministrazione della Pharmaceutical Research and Manufacturers of America. Attualmente è membro del Consiglio di Amministrazione di Edwards Life Sciences.
Organon (NYSE: OGN), una compañía global de salud enfocada en la salud femenina, ha anunciado el nombramiento de Ramona A. Sequeira en su Junta Directiva, efectivo a partir del 1 de julio de 2025. Sequeira, actualmente Presidenta de la División de Portafolio Global en Takeda Pharmaceutical Company, formará parte del Comité de Talento de la Junta.
Con este nombramiento, la Junta de Organon se amplía a 12 directores. Sequeira aporta más de 30 años de experiencia en la industria farmacéutica, incluyendo 20 años en Eli Lilly y 10 años en Takeda. En Takeda, lidera unidades de negocio en Europa, Canadá, China y en mercados en crecimiento y emergentes, además de supervisar la Unidad de Vacunas y las funciones de Estrategia Médica y Comercial Global.
Entre sus logros destacados, Sequeira fue la primera mujer en presidir la Junta Directiva de Pharmaceutical Research and Manufacturers of America. Actualmente, forma parte de la Junta Directiva de Edwards Life Sciences.
Organon (NYSE: OGN)은 여성 건강에 중점을 둔 글로벌 헬스케어 기업으로, Ramona A. Sequeira를 2025년 7월 1일부로 이사회 이사로 임명했다고 발표했습니다. 현재 Takeda Pharmaceutical Company의 글로벌 포트폴리오 부문 사장인 Sequeira는 이사회의 인재 위원회에서 활동할 예정입니다.
이번 임명으로 Organon 이사회는 12명의 이사로 확대됩니다. Sequeira는 제약 산업에서 30년 이상의 경력을 보유하고 있으며, Eli Lilly에서 20년, Takeda에서 10년을 근무했습니다. Takeda에서는 유럽, 캐나다, 중국 및 성장 및 신흥 시장의 사업부를 이끌며 백신 사업부와 글로벌 의료 및 상업 전략 기능도 총괄하고 있습니다.
Sequeira의 주요 성과 중 하나는 Pharmaceutical Research and Manufacturers of America 이사회를 최초로 여성 의장으로 이끈 것입니다. 현재 Edwards Life Sciences 이사회에도 참여하고 있습니다.
Organon (NYSE : OGN), une entreprise mondiale de soins de santé axée sur la santé des femmes, a annoncé la nomination de Ramona A. Sequeira au sein de son conseil d'administration, à compter du 1er juillet 2025. Sequeira, actuellement présidente de la division portefeuille global chez Takeda Pharmaceutical Company, siègera au comité des talents du conseil.
Cette nomination porte le conseil d'Organon à 12 membres. Sequeira apporte plus de 30 ans d'expérience dans l'industrie pharmaceutique, dont 20 ans chez Eli Lilly et 10 ans chez Takeda. Chez Takeda, elle dirige des unités commerciales en Europe, au Canada, en Chine, ainsi que sur les marchés en croissance et émergents, tout en supervisant l'unité Vaccins et les fonctions de stratégie médicale et commerciale globale.
Parmi ses réalisations notables, Sequeira a été la première femme à présider le conseil d'administration de la Pharmaceutical Research and Manufacturers of America. Elle siège actuellement au conseil d'administration d'Edwards Life Sciences.
Organon (NYSE: OGN), ein globales Gesundheitsunternehmen mit Fokus auf Frauengesundheit, hat die Ernennung von Ramona A. Sequeira in seinen Vorstand bekannt gegeben, wirksam ab dem 1. Juli 2025. Sequeira, derzeit Präsidentin der Global Portfolio Division bei Takeda Pharmaceutical Company, wird im Talentkomitee des Vorstands tätig sein.
Mit dieser Ernennung erweitert Organon seinen Vorstand auf 12 Mitglieder. Sequeira bringt über 30 Jahre Erfahrung in der Pharmaindustrie mit, davon 20 Jahre bei Eli Lilly und 10 Jahre bei Takeda. Bei Takeda leitet sie Geschäftsbereiche in Europa, Kanada, China sowie in Wachstums- und Schwellenmärkten und ist zudem verantwortlich für die Impfstoff-Sparte sowie die globale medizinische und kommerzielle Strategie.
Zu ihren bedeutenden Leistungen zählt, dass sie als erste Frau den Vorstand der Pharmaceutical Research and Manufacturers of America geleitet hat. Derzeit ist sie auch Mitglied im Vorstand von Edwards Life Sciences.
- Board strengthened with addition of experienced pharmaceutical executive
- New director brings extensive global commercial strategy expertise
- Appointment adds diversity and leadership experience to the board
- None.
Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a track record of strong execution across global markets including the
“We are excited to strengthen our Board with the appointment of Ramona Sequeira,” said Carrie Cox, Chairman of Organon’s Board of Directors. “Her deep experience in commercial strategy will be a valuable asset to Organon as we continue to seek growth opportunities for our expansive and diverse portfolio.”
In her role as President of the Global Portfolio Division, Ms. Sequeira sits on Takeda’s Global Executive Team and is responsible for leading business units across
About Organon
Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon’s scale and agile presence in fast growing international markets.
Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in
For more information, visit https://www.organon.com/ and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415558806/en/
Media Contacts:
Felicia Bisaro
(646) 703-1807
Kate Vossen
(732) 675-8448
Investor Contacts:
Jennifer Halchak
(201) 275-2711
Source: Organon & Co.
FAQ
When will Ramona Sequeira join Organon's (OGN) Board of Directors?
What role will Ramona Sequeira have on Organon's (OGN) Board?
What is Ramona Sequeira's current position before joining Organon (OGN)?
How many years of pharmaceutical industry experience does Organon's (OGN) new board member have?
